SUVN-G3031 for Narcolepsy

"The records on clinicaltrials.gov attest to the fact that this experimental trial is recruiting participants, with initial postings dating back to September 21st 2019 and recent edits made on September 9th 2022."

"Research on SUVN-G3031 dates back to 2019, when Suven Life Sciences Limited sponsored a trial with 171 participants. After successfully completing its Phase 2 evaluation stage, the drug is now being studied in further detail by the same sponsor via an active clinical study."

"SUVN-G3031 was first trialled at Research Centers of America in 2019, and has since seen 18,322 concluded clinical trials. Currently there is one active trial being conducted, primarily located near Gainesville, Georgia."

"Suven Life Sciences Limited, the trial's sponsor, requires 171 eligible patients to commence. These participants will be recruited from two sites: The Neuro Center in Gainesville and IACT Health in Lawrenceville."

"The requirements for entry into this medical experiment stipulate that participants must be at least 18 years of age and younger than 65."

"This clinical trial is recruiting 171 participants aged between 18 and 65 that suffer from narcolepsy. Other eligibility requirements include: height, weight, female birth control measures (if applicable), Epworth Sleepiness Scale score of 12 or above, Multiple Wakefulness Test time below 12 minutes, BMI ranging from 18 to 45 kg/m2, negative urine drug screen results and willingness to comply with the study protocol while signing an ICF form."

"Patients can enroll in this trial at The Neuro Center located in Gainesville, Georgia as well as IACT Health situated in Lawrenceville, Ohio and the Ohio Sleep Medicine Institute found in Dublin, Minnesota. In total there are 57 other sites available for enrollment."

"Despite being in Phase 2 of the trial, our team has surmised a safety rating of 2 for SUVN-G3031 due to existing evidence that attests its security yet lacks any efficacy data."